Company Profile

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on addressing the unmet need in diseases caused by transthyretin (TTR), amyloidosis (ATTR). It focuses on treating the disease by targeting them at their collective source by stabilizing TTR. The Company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR. AG10 binds and stabilizes TTR in the blood, preventing the formation of amyloid and halting progression of the disease.

Employees

Sector

Biotechnology & Medical Research

More about the company

21-01-27	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from S&P TMI Index	CI
21-01-27	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from S&P Global BMI Index	CI
21-01-26	Eidos Therapeutics, Inc. Announces Board Changes	CI
21-01-26	Eidos Therapeutics, Inc.(NasdaqGM:EIDX) dropped from NASDAQ Composite Index	CI
21-01-25	BridgeBio Pharma, Inc. completed the acquisition of remaining 36.3% stake in Eidos Therapeutics, Inc..	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Index	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000 Index	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Index	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2000 Growth Index	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell Small Cap Completeness Index	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell Small Cap Comp Growth Index	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 3000 Growth Index	CI
21-01-25	Eidos Therapeutics, Inc.(NasdaqGS:EIDX) dropped from Russell 2500 Growth Index	CI

21-01-26	EIDOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles (form 8-K)	AQ
21-01-26	BRIDGEBIO PHARMA, INC. : Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
21-01-26	Eidos Therapeutics : BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.	AQ
21-01-20	EIDOS THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
21-01-20	BridgeBio Pharma : Stockholders of BridgeBio Pharma Inc and Eidos Therapeutics Inc. Approve BridgeBio Pharma Inc. Acquisition Of Eidos Therapeutics Inc	AQ

Manager	Title	Age	Since
Neil Kumar CEO	Chief Executive Officer	47	2016-02-29
Jonathan Fox PSD	President	68	2016-09-30
Uma Sinha CTO	Chief Tech/Sci/R&D Officer	69	2016-05-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
21-01-25	William David Lis	Issuer sale	Director	86,112	0.2216%
21-01-25	Cameron Turtle	Tender	Director	113,325	0.2916%
21-01-25	BRIDGEBIO PHARMA, INC.	Buy	Company	14,428,836	37.1285%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EIDOS THERAPEUTICS, INC.	-4.85%	-4.63%	-	-	4.75B
ARGENX SE	+2.87%	+4.57%	+68.97%	+119.22%	55.19B
WUXI APPTEC CO., LTD.	+4.00%	+7.51%	+63.67%	+68.77%	45.75B
BIONTECH SE	-0.77%	-0.67%	-15.34%	-15.95%	22.98B
INSMED INCORPORATED	+2.93%	+1.17%	-3.97%	+384.78%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+1.50%	+3.93%	+27.35%	-17.35%	16.26B
GENMAB A/S	+1.16%	+3.86%	+20.23%	-36.42%	15.42B
EXELIXIS, INC.	-1.08%	-3.11%	+27.20%	+158.30%	13.05B
PHARMAESSENTIA CORPORATION	+3.30%	+15.02%	+133.24%	+273.89%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.99%	-5.92%	+22.16%	-	12.37B
Average	+1.10%	+2.16%	+38.17%	+116.90%	23.8B
Weighted average by Cap.	+2.08%	+3.17%	+43.54%	+108.89%

Eidos Therapeutics, Inc. Stock

Stocks

EIDX

US28249H1041

Biotechnology & Medical Research

Latest news : Eidos Therapeutics, Inc.

Press Releases: Eidos Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Eidos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile